Scan to Download ios&Android APP

Trade Five Prime Therapeutics, Inc. - FPRX CFD

37.95
0.05%

Five Prime Therapeutics, Inc. live chart

Still looking for a broker you can trust?
Capital.com Group
400,000+

Traders

90,000+

Active clients monthly

$65,000,000+

Monthly investing volume

$29,000,000+

Withdrawn each month

  • Summary
  • Historical Data
Trading Conditions
Long position overnight fee
-0.0225%
Short position overnight fee
-0.0219%
Overnight fee time
21:00 (UTC)
Min traded quantity
1
Currency
USD
Margin
20%
Stock exchange
United States of America
Commission on trade
0%
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2021 37.95 0.03 0.08% 37.92 37.95 37.91
Apr 14, 2021 37.93 0.04 0.11% 37.89 37.93 37.89
Apr 13, 2021 37.89 0.00 0.00% 37.89 37.91 37.89
Apr 12, 2021 37.88 -0.02 -0.05% 37.90 37.90 37.87
Apr 9, 2021 37.88 0.01 0.03% 37.87 37.90 37.85
Apr 8, 2021 37.85 -0.03 -0.08% 37.88 37.89 37.84
Apr 7, 2021 37.87 1.50 4.12% 36.37 37.91 36.37
Apr 6, 2021 37.91 0.05 0.13% 37.86 37.92 37.86
Apr 5, 2021 37.62 -0.14 -0.37% 37.76 37.85 37.55
Apr 1, 2021 37.76 0.08 0.21% 37.68 37.76 37.65
Mar 31, 2021 37.64 -0.06 -0.16% 37.70 37.80 37.64
Mar 30, 2021 37.68 -0.02 -0.05% 37.70 37.72 37.67
Mar 29, 2021 37.67 -0.07 -0.19% 37.74 37.76 37.67
Mar 26, 2021 37.82 0.10 0.27% 37.72 37.84 37.67
Mar 25, 2021 37.72 0.01 0.03% 37.71 37.84 37.66
Mar 24, 2021 37.67 -0.03 -0.08% 37.70 37.79 37.66
Mar 23, 2021 37.68 -0.01 -0.03% 37.69 37.78 37.67
Mar 22, 2021 37.71 -0.02 -0.05% 37.73 37.81 37.65
Mar 19, 2021 37.83 0.17 0.45% 37.66 37.88 37.60
Mar 18, 2021 37.61 -0.18 -0.48% 37.79 37.81 37.60

Content 2
Content 2

Five Prime Therapeutics, Inc. Company profile

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company''s product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company''s BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Industry: Bio Therapeutic Drugs

111 Oyster Point Blvd
Two Corporate Drive
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People Also Watch

US Tech 100

11,656.60 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0093%
Short position overnight fee 0.0008%
Overnight fee time 21:00 (UTC)
Spread 1.0

Still looking for a broker you can trust?

Join the 400.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading